贝达喹啉治疗美国耐多药结核病的病例系列
该病例系列回顾性分析了2012年9月至2016年8月美国4个结核病项目中14例使用贝达喹啉治疗耐多药结核病(MDR TB)的患者,其中7例(50%)为MDR,4例(29%)为准广泛耐药(pre-XDR),3例(21%)为广泛耐药(XDR)。所有患者均在开始贝达喹啉后平均71天(26-116天)内实现痰培养转阴,12例(86%)完成治疗,1例(7%)因不良事件需停用贝达喹啉。常见不良事件为周围神经病变7/14(50%)和QTc间期延长6/14(43%)。
要点
- 贝达喹啉治疗MDR/XDR TB患者痰培养转阴平均71天,86%完成治疗。
- 1例(7%)因不良事件停用贝达喹啉,安全性总体可接受。
- 周围神经病变(50%)和QTc延长(43%)为常见不良事件,需监测。
核心结论
- 14例患者中仅1例(7%)因不良事件需停用贝达喹啉,安全性、痰培养转阴及治疗完成率支持贝达喹啉用于MDR/XDR TB治疗。
研究设计与样本
- 回顾性病例系列,通过4个结核病项目收集2012年9月至2016年8月期间开始贝达喹啉治疗的MDR TB患者数据,采用标准化抽象工具,单变量分析。
主要发现
- 14例患者中7例(50%)为MDR,4例(29%)为准XDR,3例(21%)为XDR;全部为肺结核,5例(36%)合并肺外结核,9/13(69%)涂片阳性。
- 所有患者实现痰培养转阴,平均71天(范围26-116天),其中5例在开始贝达喹啉后转阴。
- 12例(86%)完成治疗,1例(7%)移居国外;1例(7%)出现QTc间期延长>500毫秒,停药20个月后死于与药物无关的原因。
- 常见不良事件:周围神经病变7/14(50%),QTc间期延长6/14(43%)。
临床怎么用
- 贝达喹啉可用于MDR/XDR TB联合治疗,但需监测周围神经病变和QTc间期延长。
局限性
- 回顾性病例系列,样本量小(14例),单变量分析,来自4个结核病项目,可能存在选择偏倚和信息偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2012, the Food and Drug Administration approved use of bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis (MDR TB). We describe treatment outcomes, safety, and tolerability of bedaquiline in our case series. METHODS: Data on patients started on bedaquiline for MDR TB between September 2012 and August 2016 were collected retrospectively through 4 TB programs using a standardized abstraction tool. Data were analyzed using univariate methods. Adverse events were graded using the Common Terminology Criteria for Adverse Events. RESULTS: Of 14 patients, 7 (50%) had MDR, 4 (29%) had pre-extensively drug-resistant (XDR), and 3 (21%) had XDR TB. All had pulmonary TB, 5 (36%) had pulmonary and extrapulmonary TB, and 9/13 (69%) were smear positive. One patient (7%) had HIV coinfection, 5 (36%) had diabetes mellitus, and 5/14 (36%) had previous treatment TB. All patients were non-US-born and 5/14 (36%) had private insurance. All patients achieved sputum culture conversion within a mean of 71 days (26-116); 5 after starting bedaquiline. Twelve (86%) completed treatment and 1 (7%) moved out of the country. One patient (7%) had QTc prolongation >500 milliseconds and died 20 months after discontinuing bedaquiline of a cause not attributable to the drug. Common adverse events were peripheral neuropathy 7/14 (50%), not customarily associated with bedaquiline use, and QTc prolongation 6/14 (43%). CONCLUSIONS: Of 14 patients, 1 (7%) had an adverse event necessitating bedaquiline discontinuation. Safety, culture conversion, and treatment completion in this series (7%) support use of bedaquiline for the treatment of MDR/XDR TB.
引用
- Mase S, Chorba T, Parks S, et al. Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States. Clin Infect Dis. 2020. PMID: 31556947. doi:10.1093/cid/ciz914
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。